Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc KHTRF


Primary Symbol: T.GUD

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > Knights Loans
View:
Post by EbbFlow88 on Aug 12, 2022 12:02pm

Knights Loans

I can't remember but I think the number of loans has decreased. Seems like they have been letting them run off and not renewing. 

The Synergy loan is maturing in 2022 and 60 degree pharma and M8 in 2023. That would be about $24M in proceeds to redirect to M&A. 

They already said they will not be investing in any new funds but does anyone have any ideas about loans?
Comment by MrMugsy on Aug 13, 2022 11:19am
I think they would still entertain loans but Samira is interested in real collateral (e.g. Samira wasn't interested in the Appili deal for that reason but Loadzone Holdings was). As a one-stop-shop for young and upcoming drug developers, I think there is always room for negotiation and to offer cash as a loan or cash for ownership rights.  Many factors at play in the final deal decisions
Comment by curiousj on Aug 13, 2022 12:21pm
any news on synergy as a going concern? loan repmt doesn't seem promising
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities